179 related articles for article (PubMed ID: 37975412)
21. The MYCN 5' UTR as a therapeutic target in neuroblastoma.
Volegova MP; Brown LE; Banerjee U; Dries R; Sharma B; Kennedy A; Porco JA; George RE
Cell Rep; 2024 May; 43(5):114134. PubMed ID: 38662542
[TBL] [Abstract][Full Text] [Related]
22. MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma.
Tao L; Mohammad MA; Milazzo G; Moreno-Smith M; Patel TD; Zorman B; Badachhape A; Hernandez BE; Wolf AB; Zeng Z; Foster JH; Aloisi S; Sumazin P; Zu Y; Hicks J; Ghaghada KB; Putluri N; Perini G; Coarfa C; Barbieri E
Nat Commun; 2022 Jun; 13(1):3728. PubMed ID: 35764645
[TBL] [Abstract][Full Text] [Related]
23. KAP1 stabilizes MYCN mRNA and promotes neuroblastoma tumorigenicity by protecting the RNA m
Yang Y; Zhang Y; Chen G; Sun B; Luo F; Gao Y; Feng H; Li Y
J Exp Clin Cancer Res; 2024 May; 43(1):141. PubMed ID: 38745192
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T
Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952
[TBL] [Abstract][Full Text] [Related]
25. The long non-coding RNA MYCNOS-01 regulates MYCN protein levels and affects growth of MYCN-amplified rhabdomyosarcoma and neuroblastoma cells.
O'Brien EM; Selfe JL; Martins AS; Walters ZS; Shipley JM
BMC Cancer; 2018 Feb; 18(1):217. PubMed ID: 29466962
[TBL] [Abstract][Full Text] [Related]
26.
Dzieran J; Rodriguez Garcia A; Westermark UK; Henley AB; Eyre Sánchez E; Träger C; Johansson HJ; Lehtiö J; Arsenian-Henriksson M
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1229-E1238. PubMed ID: 29374092
[TBL] [Abstract][Full Text] [Related]
27.
Maeshima R; Moulding D; Stoker AW; Hart SL
Nucleic Acid Ther; 2020 Aug; 30(4):237-248. PubMed ID: 32240058
[TBL] [Abstract][Full Text] [Related]
28. MTHFD1 regulates the NADPH redox homeostasis in MYCN-amplified neuroblastoma.
Guan J; Li M; Wang Y; Zhang Y; Que Y; Lu S; Wang J; Zhu J; Huang J; Zhen Z; Sun F; Song M; Zhang Y
Cell Death Dis; 2024 Feb; 15(2):124. PubMed ID: 38336749
[TBL] [Abstract][Full Text] [Related]
29. Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC-Driven Cancer Progression.
Gao J; Jung M; Mayoh C; Venkat P; Hannan KM; Fletcher JI; Kamili A; Gifford AJ; Kusnadi EP; Pearson RB; Hannan RD; Haber M; Norris MD; Somers K; Henderson MJ
Cancer Res; 2020 Sep; 80(17):3706-3718. PubMed ID: 32651259
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of the ALDH18A1-MYCN positive feedback loop attenuates
Guo YF; Duan JJ; Wang J; Li L; Wang D; Liu XZ; Yang J; Zhang HR; Lv J; Yang YJ; Yang ZY; Cai J; Liao XM; Tang T; Huang TT; Wu F; Yang XY; Wen Q; Bian XW; Yu SC
Sci Transl Med; 2020 Feb; 12(531):. PubMed ID: 32075946
[No Abstract] [Full Text] [Related]
31. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
[TBL] [Abstract][Full Text] [Related]
32. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.
Dolman ME; Poon E; Ebus ME; den Hartog IJ; van Noesel CJ; Jamin Y; Hallsworth A; Robinson SP; Petrie K; Sparidans RW; Kok RJ; Versteeg R; Caron HN; Chesler L; Molenaar JJ
Clin Cancer Res; 2015 Nov; 21(22):5100-9. PubMed ID: 26202950
[TBL] [Abstract][Full Text] [Related]
33. Silencing of the Long Noncoding RNA MYCNOS1 Suppresses Activity of MYCN-Amplified Retinoblastoma Without RB1 Mutation.
Saengwimol D; Chittavanich P; Laosillapacharoen N; Srimongkol A; Chaitankar V; Rojanaporn D; Aroonroch R; Suktitipat B; Saisawang C; Svasti S; Hongeng S; Kaewkhaw R
Invest Ophthalmol Vis Sci; 2020 Dec; 61(14):8. PubMed ID: 33270844
[TBL] [Abstract][Full Text] [Related]
34. The RNA-helicase DDX21 upregulates CEP55 expression and promotes neuroblastoma.
Putra V; Hulme AJ; Tee AE; Sun JQJ; Atmadibrata B; Ho N; Chen J; Gao J; Norris MD; Haber M; Kavallaris M; Henderson MJ; McCarroll J; Trahair T; Liu T; Liu PY
Mol Oncol; 2021 Apr; 15(4):1162-1179. PubMed ID: 33497018
[TBL] [Abstract][Full Text] [Related]
35. LncRNA AC142119.1 facilitates the progression of neuroblastoma by epigenetically initiating the transcription of MYCN.
Yang R; Liu N; Li T; Liu F; Zhang J; Zhao H; Zou L; He X
J Transl Med; 2023 Sep; 21(1):659. PubMed ID: 37741985
[TBL] [Abstract][Full Text] [Related]
36. Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma.
Zhai L; Balachandran A; Larkin R; Seneviratne JA; Chung SA; Lalwani A; Tsubota S; Beck D; Kadomatsu K; Beckers A; Durink K; De Preter K; Speleman F; Haber M; Norris MD; Swarbrick A; Cheung BB; Marshall GM; Carter DR
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958555
[No Abstract] [Full Text] [Related]
37. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
Wyce A; Ganji G; Smitheman KN; Chung CW; Korenchuk S; Bai Y; Barbash O; Le B; Craggs PD; McCabe MT; Kennedy-Wilson KM; Sanchez LV; Gosmini RL; Parr N; McHugh CF; Dhanak D; Prinjha RK; Auger KR; Tummino PJ
PLoS One; 2013; 8(8):e72967. PubMed ID: 24009722
[TBL] [Abstract][Full Text] [Related]
38. MYCN Directly Targets NeuroD1 to Promote Cellular Proliferation in Neuroblastoma.
Lu F; Mu B; Jin G; Zhu L; Mu P
Oncol Res; 2022 May; 29(1):1-10. PubMed ID: 34937609
[TBL] [Abstract][Full Text] [Related]
39. A mouse model of MYCN-driven retinoblastoma reveals MYCN-independent tumor reemergence.
Wu N; Jia D; Bates B; Basom R; Eberhart CG; MacPherson D
J Clin Invest; 2017 Mar; 127(3):888-898. PubMed ID: 28165337
[TBL] [Abstract][Full Text] [Related]
40. GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma.
Dong Z; Yeo KS; Lopez G; Zhang C; Dankert Eggum EN; Rokita JL; Ung CY; Levee TM; Her ZP; Howe CJ; Hou X; van Ree JH; Li S; He S; Tao T; Fritchie K; Torres-Mora J; Lehman JS; Meves A; Razidlo GL; Rathi KS; Weroha SJ; Look AT; van Deursen JM; Li H; Westendorf JJ; Maris JM; Zhu S
Cancer Res; 2021 Jun; 81(11):2995-3007. PubMed ID: 33602789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
